Cargando…

Examining the Early Period Effect of Nilotinib on Hearing: An Experimental Study

OBJECTIVES: Nilotinib has very few side effects, including neutropenia, thrombocytopenia, cardiotoxicity, high pancreatic lipase, ischemia, and vascular occlusion. We aimed to investigate whether short-term administration of nilotinib had ototoxic effects in rats. MATERIALS AND METHODS: Wistar-albin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bora, Adem, Durmuş, Kasım, Terzi, Hatice, Altuntaş, Emine Elif
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The European Academy of Otology and Neurotology 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224425/ https://www.ncbi.nlm.nih.gov/pubmed/31287435 http://dx.doi.org/10.5152/iao.2019.5908

Ejemplares similares

Does the use of recombinant TSH in preparation for I-131 scintigraphy scan affect hearing function?
por: Doğan, Mehtap, et al.
Publicado: (2018)

Strontium chloride hexahydrate as a candidate molecule for long-term treatment of allergic rhinitis
por: Altuntas, Emine Elif, et al.
Publicado: (2017)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Factors Affecting Permanent Sensorineural Hearing Loss and Bone Conduction in Patients After Receiving Radiotherapy to the Head and Neck Region
por: Yücel, Birsen, et al.
Publicado: (2022)

Effects of nilotinib on regulatory T cells: the dose matters
por: Fei, Fei, et al.
Publicado: (2010)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
por: Pagan, Fernando, et al.
Publicado: (2016)

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
por: Turner, Raymond S., et al.
Publicado: (2020)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics
por: Alhazzani, Khalid, et al.
Publicado: (2023)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
por: Okamoto, Yuji, et al.
Publicado: (2022)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Effects of imatinib and nilotinib on the whole transcriptome of cultured murine osteoblasts
por: Kirschner, Gyöngyi, et al.
Publicado: (2016)

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease
por: Pagan, Fernando L., et al.
Publicado: (2020)

Assessment of mucociliary clearance as an indicator of nasal function in patients with COVID-19: a cross-sectional study
por: Koparal, Mehtap, et al.
Publicado: (2020)

Nilotinib-induced Perforating Folliculitis: Two Cases
por: Saraswat, Neerja, et al.
Publicado: (2018)

Nilotinib: QTc prolongation: 2 case reports
Publicado: (2021)

Effects of the Lunar Cycle, Seasons and the Meteorological Factors on Peripheral Vertigo
por: Koparal, Mehtap, et al.
Publicado: (2022)

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
por: Gordon, Jessica K., et al.
Publicado: (2015)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Hepatitis B Virus Reactivation under Treatment with Nilotinib
por: Temel, Tuncer, et al.
Publicado: (2015)

Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
por: Contreras, Osvaldo, et al.
Publicado: (2018)

A Case of Severe, Nilotinib-Induced Liver Injury
por: Belopolsky, Yuliya, et al.
Publicado: (2019)

Nilotinib-induced liver injury: A case report
por: Tan, Youwen, et al.
Publicado: (2020)

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
por: Paramarta, Jacqueline E., et al.
Publicado: (2016)

Experience with an Affective Robot Assistant for Children with Hearing Disabilities
por: Uluer, Pinar, et al.
Publicado: (2021)

Examinations of effects of socio-demographic features and disease-related data of patients with hemodialysis on the quality of life
por: Togay, Elif, et al.
Publicado: (2023)

Pleural Effusion: A Rare Side Effect of Nilotinib—A Case Report
por: Üsküdar Teke, Hava, et al.
Publicado: (2014)

Different anti-remodeling effect of nilotinib and fluticasone in a chronic asthma model
por: Kang, Hye Seon, et al.
Publicado: (2016)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
por: Santoleri, Fiorenzo, et al.
Publicado: (2013)

Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
por: Tefferi, A
Publicado: (2013)

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_42c062an8t66n2s8qbmo9ga91s